RCAG
BMRN icon

Rehmann Capital Advisory Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Rehmann Capital Advisory Group’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-20
Closed -$1.71K – 1717
2019
Q2 		$1.71K Buy
20
+3
+18% +$257 ﹤0.01% 1816
2019
Q1 		$1.51K Buy
+17
New +$1.58K ﹤0.01% 1844

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Rehmann Capital Advisory Group's BMRN Position: Q3 2019 in Review

Rehmann Capital Advisory Group sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2019, closing a stake of 20 shares — an estimated $1.71K sold.

Rehmann Capital Advisory Group first reported a position in BMRN in Q1 2019 and held it in 2 quarters. The position peaked at $1.71K in Q2 2019. 436 funds tracked by Wall St. Rank hold BMRN as of Q3 2019.

  • Rehmann Capital Advisory Group reported no remaining BioMarin Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Rehmann Capital Advisory Group sold 20 BioMarin Pharmaceuticals shares in Q3 2019, an estimated $1.71K.
  • Rehmann Capital Advisory Group first reported a position in BioMarin Pharmaceuticals in Q1 2019 and held it in 2 quarters.
  • Rehmann Capital Advisory Group's BioMarin Pharmaceuticals position peaked at $1.71K in Q2 2019.
  • 436 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2019.

Based on Rehmann Capital Advisory Group's 13F filing for Q3 2019, filed 2 Jan 2020.